Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 14;11:609689. doi: 10.3389/fimmu.2020.609689

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Kim, Yi, Kim, Lee, Chung, Ha, Cho, Kim, Ko, Cheon, Hong and Chang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Oral CG-598 treatment has a comparable protective effect to TNF blocker against colitis. Mice were fed with 2.5% DSS in drinking water for five days followed by normal water afterwards (n=8 per group). Mice were treated with 15 mg/kg CG-598 by oral gavage once every day. Animals were treated with anti-mouse TNF-α antibody (0.5 mg per mouse) intraperitoneally at days 4, 6, 8, and 10. (A) Body weight and (B) disease activity index following DSS treatment. Two-way ANOVA. (C) Colon length at day 12. (D) Cytokines from colon tissue homogenates. (E) Serum lipopolysaccharide concentrations. (F) Bacterial CFUs cultured from MLN (left) and spleen (right). (G) Serum inflammatory cytokines. Data are representative of three independent experiments. One-way ANOVA. Data are shown as mean ± SEM, ns, not significant, *p < 0.05, **p < 0.01, ***p < 0.001, compared to the vehicle group.